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Epstein-Barr virus transformed human lymphocytes despite the presence of up to 500 ,uM acyclovir
[9-(2-hydroxyethoxymethyl)guanine], a viral DNA polymerase inhibitor. The transformed cells contained
multiple Epstein-Barr virus genome copy numbers. Functional viral DNA polymerase is probably not required
for cell transformation and the initial amplification of the viral genome.
Epstein-Barr virus (EBV) is a transforming herpesvirus
which, on infection of human B lymphocytes in vitro, is
capable of producing permanent lymphoblastoid cell lines.
This effect mirrors the consequence of infection of B lym-
phocytes in vivo (14). In its latent state, the viral genome
confers on the host cell the potential for unlimited cell
growth. A critical step in EBV-induced cell transformation
probably involves early EBV replication Within the infected
target cell. Human umbilical cord lymphocytes that have
been transformed by EBV generally contain several copies
of the EBV genome in its episomal form but do not freely
synthesize viral DNA or produce virus (1, 12). A related
question, therefore, is whether EBV-induced DNA polymer-
ase is needed for transformation. These basic questions are
also important because of the interest in applying antiviral
drugs in the treatment of the EBV-induced polyclonal lym-
phoproliferative diseases that occur in irnmunocompromised
persons (13, 18).
In vitro use of the viral DNA polymerase inhibitor
phosphonoacetic acid (PAA) as a probe of early transforma-
tional events has produced results with conflicting interpre-
tations. Thorley-Lawson and Strominger (19, 20) and Lemon
et al. (8) have reported the absence of cell outgrowth in
lymphocytes infected with EBV and maintained on PAA.
However, Lemon et al. did note increased cellular nucleic
acid synthesis consistent with beginning transformation (8).
Moreover, the EBV nuclear antigen (EBNA), a marker of
EBV-induced cell transformation, was detected in some
PAA-treated cells (20). Rickinson and Epstein have de-
scribed not only the establishment of permanent lymphoblas-
toid cell lines after comparable exposures of cells to PAA,
but also apparent amplification of the incoming viral genome
(16). These discrepancies may be due in part to dose-depend-
ent inhibition by PAA not only of viral (10) but also of
cellular DNA polymerase (7, 10). To eliminate any ambigu-
ity introduced in these results by the lack of specificity of
PAA, we have used the acyclic nucleoside analog acyclovir
[9-(2-hydroxyethoxymethyl)guanine] (ACV) as a highly se-
lective inhibitor of EBV-specific DNA polymerase to inves-
tigate EBV-induced transformation of human umbilical cord
lymphocytes.
ACV was a gift of the Burroughs Wellcome Co. Clinical
isolates of EBV from saliva of persons with acute infectious
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mononucleosis were obtained by throat washings with phos-
phate-buffered saline solution. Filtered samples capable of
producing permanent, EBNA-positive cell lines from umbil-
ical cord lymphocytes were selected for use in the assays
described below. Mixed populations of umbilical cord lym-
phocytes were prepared by centrifugation of heparinized
cord blood on Ficoll-Isopaque (Pharmacia Fine Chemicals)
(2). B-cell enrichment of adult peripheral blood lymphocytes
was accomplished by erythrocyte rosetting (21). EBV-in-
duced cell transformation was confirmed by detection of
EBNA (15). Numbers of EBV genome equivalents in dupli-
cate lines from ACV- and mock-treated groups were deter-
mined by nucleic acid hybridization as previously described
(11).
A transformation centers assay similar to that described
by Henderson et al. (6) was performed to study the effects of
ACV on the induction of lymphocyte transformation by
EBV isolates (Table 1). We obtained cell outgrowth and
establishment of permanent EBNA-positive lytnphoblastoid
cell lines with two different preparations of umbilical cord
lymphocytes after exposure to EBV in the presence of up to
500 ,uM ACV, a concentration at least five times that
required for complete inhibition of EBV DNA synthesis in
superinfected Raji cells (4, 9). Efficiency of transformation in
ACV-treated cells was identical to that in control cultures at
levels of up to 250 ,uM, 25 times the 90% effective dose of the
drug for EBV (4, 9). There was no significant delay in
establishing transformation (Table 1). Only at 500 pLM did
transformation efficiency decrease, presumably due to drug
toxicity.
Drug-induced enhancement of transformation did not oc-
cur. This provides evidence against a cytolytic stage in a
subset of lymphocytes shortly after infection which, if
inhibited by the drug, would increase the chances for viral
latency, cell survival, and eventual transformation (8). This
point is worth noting given the possibility that the clinical
isolates used might contain both lytic and transforming
strains of virus (17). None of the 48 wells containing umbil-
ical cord lymphocytes maintained in 100 ,uM ACV sponta-
neously transformed in the absence of EBV exposure.
ACV requires phosphorylation by either viral or cellular
enzymes to be effective against EBV-specific DNA polymer-
ase (3). EBV-positive and -negative lymphoid cell lines and
fresh peripheral lymphocyte preparations from both EBV-
seropositive and -seronegative adult donors are capable of
phosphorylating drug in vitro (3). To ensure that our results
were not a consequence of inadequate phosphorylation of
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ACV in umbilical cord lymphocytes, we also studied a B
lymphocyte-enriched preparation from the peripheral blood
of an EBV-serotlegative adult whose uninfected cells were
previously shown to be capable of ACV phosphorylation in
vitro (3). EBV-induced cell transformation in the presence of
ACV occurred in all cases regardless of the source of the
lymphocytes and with all three viral isolates used.
Previous determinations have established that most cell
lines produced by in vitro EBV infection of umbilical cord
blood cells contain 10 to 15 copies of the EBV genome per
cell (12). Because we achieved cell transformation at ACV
concentrations capable of completely inhibiting viral poly-
merase-directed EBV replication, we measured the copy
number of EBV genomes in cell lines established in ACV-
containing and control medium (Table 2). EBV DNA ge-
nome equivalents were estimated from levels of hybridiza-
tion to total cellular DNA with a tritiated cRNA probe
derived from the cloned BamHI V fragment of EBV DNA.
The probe was first calibrated by hybridization with known
amounts of purified viral DNA from Raji cells (11). Umbili-
cal cord lymphocytes transformed in ACV-free medium
contained an average of seven genome equivalents per cell,
whereas cells transformed in the presence of 100 FM ACV
contained an average of six.
TABLE 1. Transformation of human umbilical cord lymphocytes
by EBV in the presence of the viral DNA polymerase inhibitor
ACV"
ACV No. of EBV Wells transformed/ No. of Mean time to
(>M) exposed cells total wellsb transformants transformation
per well per 105 cells (days)
0 l0o 10/12 0.8 46
104 4/12 53
l03 0/12
10 i05 10/12 0.8 46
104 3/12 43
103 0/12
100 105 10/12 0.8 58
104 0/12
103 1/12 66
250 105 10/12 0.8 50
104 0/12
103 0/12
500 105 5/12 0.4 63
104 1/12 66
103 0/12
" Human umbilical cord lymphocytes (2 x 106) were incubated for 1 h at
37°C with 0.2 ml of filtered throat washings from patients with infectious
mononucleosis. Control or ACV-containing medium (RPMI 1640, 20% fetal
calf serum) was added to cells, and cultures were incubated for 24 h at 37°C in
5% CO,. The tnedium was removed, and the cells were incubated for 1 h in
human serum containing EBV-neutralizing antibodies (diluted 1:10 in control
or ACV medium) to eliminate all extracellular virus. Cells were washed twice
and diluted to concentrations of 106, 105, and 104 lymphocytes per ml. One-
tenth milliliter of each lymphocyte dilution was added to 12 replicate wells of a
microassay plate containing feeder cells prepared from autochthonous, nonin-
fected lymphocytes to give a final cell number in all wells of 2 x 105 cells. The
cultures were incubated at 37°C in 5% CO2 and fed twice weekly with control
or ACV medium by replacing half of the medium. Controls consisted of mock-
infested umbilical cord lymphocytes and lymphocytes exposed to freeze-
thawed extracts and washings of EBV-exposed cells after treatment with EBV
neutralizing antibody.
b Transformation was judged microscopically on the basis of obvious cell
growth and clumping. Only wells producing permanent EBNA-positive cell
lines on passage were called transformed. Final results were scored at 10
weeks. Efficiency of transformation was calculated as (number of transformed
wells)/[(total number of cells per well) (number of wells)l.
TABLE 2. EBV genomes in newly transformed umbilical cord
lymphocytes'
Transformed No. of EBV genome equivalents in:
lymphocytes
from cell line: Control medium ACV medium
1 9 3
2 6 9
"Duplicate cell lines 1 and 2 from mock- and ACV-treated cultures were
established. Total cellular DNA was extracted from 4 x 107 ACV- and mock-
treated cells and affixed to nitrocellulose filters. EBV DNA sequences were
estimated from levels of hybridization with a 3H-labeled cRNA probe which
had been calibrated by hybridization with various known amounts of purified
viral DNA. Total DNA per filter was quantitated by a diphenylamine assay
(11).
The presence of multiple genome copy numbers in cells
transformed in the presence of high concentrations of a viral
polymerase inhibitor confirms the findings of Rickinson and
Epstein with PAA (16). The almost identical EBV genome
number in cells transformed in ACV containing medium and
in control medium makes it unlikely that viral DNA polymer-
ase is involved in any amplification of the incoming viral
genome. The rnultiple genome number may reflect replica-
tion of the EBV genome by the host polymerase, which is at
least 100-fold less sensitive to ACV triphosphate than is
EBV DNA polymerase (5). Replication of EBV genomes in
the episomal form is unaffected by ACV and other potent
inhibitors of herpesvirus DNA polymerases (9). Although
transformation is believed to occur according to single-hit
kinetics, another possibility is that the transformed cells
represent progeny of lymphocytes infected at a multiplicity
of infection greater than 1, an event made unlikely by the
virus concentrations present in the throat washings used.
These results suggest that functional viral DNA polymer-
ase may not be necessary for induction of cell transforma-
tion, but the relationship of early viral replication to the
transformation process remains unknown. The replication
and maintenance of a limited copy number of EBV episomes
may be crucial to transformation, but the apparent role of
host rather than viral DNA polymerase in this process
makes the use of viral polymerase-active drugs for treatment
of EBV-transformed cells of questionable value.
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